6-Mercaptopurine, monocytes, and atherosclerosis

Arterioscler Thromb Vasc Biol. 2010 Aug;30(8):1494-6. doi: 10.1161/ATVBAHA.110.208264.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Animals
  • Apolipoprotein E3 / genetics
  • Apolipoprotein E3 / metabolism
  • Apoptosis / drug effects
  • Atherosclerosis / genetics
  • Atherosclerosis / immunology
  • Atherosclerosis / metabolism
  • Atherosclerosis / pathology
  • Atherosclerosis / prevention & control*
  • Cell Adhesion / drug effects
  • Chemokine CCL2 / metabolism
  • Chemotaxis / drug effects
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / pharmacology*
  • Inflammation Mediators / metabolism
  • Integrin alpha4beta1 / metabolism
  • Macrophages / drug effects*
  • Macrophages / immunology
  • Macrophages / metabolism
  • Macrophages / pathology
  • Mercaptopurine / administration & dosage
  • Mercaptopurine / pharmacology*
  • Mice
  • Monocytes / drug effects*
  • Monocytes / immunology
  • Monocytes / metabolism
  • Monocytes / pathology
  • Platelet Endothelial Cell Adhesion Molecule-1 / metabolism
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • bcl-X Protein / metabolism

Substances

  • Apolipoprotein E3
  • CCL2 protein, human
  • Ccl2 protein, mouse
  • Chemokine CCL2
  • Immunosuppressive Agents
  • Inflammation Mediators
  • Integrin alpha4beta1
  • Platelet Endothelial Cell Adhesion Molecule-1
  • Proto-Oncogene Proteins c-bcl-2
  • bcl-X Protein
  • Mercaptopurine